TLM has one of the largest field research operations in the world of leprosy. The Leprosy Field Research in Bangladesh Program conducted the COLEP study - a randomised controlled trial of a large population (>20,000 contacts) which showed the effectiveness of a single dose of rifampicin (SDR-PEP) in preventing leprosy in contacts.
(Implementation research in Mozambique and Nigeria)
In this project we work with NLR and the national leprosy programmes to implement SDR-PEP in Mozambique and Nigeria. We aim to interrupt the spread and devastating effects of leprosy through well thought-out interventions targeting a range of stakeholders. The governments of both countries have shown enthusiasm and willingness to work together with the partners in this project to introduce SDR-PEP into their leprosy control programmes and improve care for persons affected.
(Clinical trial in Bangladesh and Nepal and in a number of other non-TLM countries)
TLM and NLR have again joined hands to test an enhanced PEP regimen in Bangladesh and Nepal. The project’s multi-centre research programme uses a new, more robust preventive chemotherapy regimen. SDR-PEP reduces the risk of leprosy among contacts of new patients by 57%. We expect that three doses of the new PEP++ regimen, a combination of rifampicin/clarithromycin is expected to be 80-90% effective. The medication will be administered to a random sample of close contacts in multiple doses. These people are more likely to harbour a higher number of leprosy bacilli than the general population or may be infected without any visible symptoms yet. More than 800,000 will receive preventative treatment across the five countries involved (Bangladesh, Brazil, India, Indonesia, Nepal).
